why choose us

Course: Asymptomatic and Symptomatic SARS-CoV-2 Infections After BNT162b2 Vaccination in a Routinely Screened Workforce

CME Credits: 1.00

Released: 2021-05-06

A 2-dose regimen of the BNT162b2 vaccine (Pfizer-BioNTech) against SARS-CoV-2 was authorized in December 2020 based on reported 94.8% efficacy. Although an association between vaccination and a reduction in symptomatic disease has been well described, an association with asymptomatic infection remains unclear.,


Educational Objective
To identify the key insights or developments described in this article


View Full Course